Free Trial

Thermo Fisher Scientific (TMO) Stock Forecast & Price Target

Thermo Fisher Scientific logo
$524.05 +7.36 (+1.42%)
(As of 12/20/2024 05:31 PM ET)

Thermo Fisher Scientific - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
17

Based on 21 Wall Street analysts who have issued ratings for Thermo Fisher Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 4 have given a hold rating, 16 have given a buy rating, and 1 has given a strong buy rating for TMO.

Consensus Price Target

$652.30
24.47% Upside
According to the 21 analysts' twelve-month price targets for Thermo Fisher Scientific, the average price target is $652.30. The highest price target for TMO is $718.00, while the lowest price target for TMO is $610.00. The average price target represents a forecasted upside of 24.47% from the current price of $524.05.
Get the Latest News and Ratings for TMO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Thermo Fisher Scientific and its competitors.

Sign Up

TMO Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
17 Buy rating(s)
15 Buy rating(s)
15 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$652.30$649.33$647.78$597.53
Forecasted Upside24.47% Upside26.51% Upside6.13% Upside12.94% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

TMO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Thermo Fisher Scientific Stock vs. The Competition

TypeThermo Fisher ScientificMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside24.47% Upside25,827.32% Upside14.53% Upside
News Sentiment Rating
Neutral News

See Recent TMO News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/13/2024Bank of America
3 of 5 stars
 Lower TargetBuy ➝ Buy$675.00 ➝ $660.00+26.05%
10/24/2024Sanford C. Bernstein
3 of 5 stars
 Lower TargetMarket Perform ➝ Market Perform$625.00 ➝ $620.00+10.17%
10/24/2024Royal Bank of Canada
4 of 5 stars
 Lower TargetOutperform ➝ Outperform$767.00 ➝ $718.00+27.51%
10/24/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$680.00 ➝ $665.00+17.72%
10/24/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$630.00 ➝ $620.00+9.38%
10/24/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Couillard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$670.00 ➝ $660.00+16.46%
10/24/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$632.00 ➝ $622.00+7.89%
10/23/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$620.00 ➝ $610.00+6.63%
10/22/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$656.00 ➝ $686.00+16.92%
10/22/2024Bernstein Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$565.00 ➝ $625.00+6.30%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$680.00+13.74%
10/1/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Johnson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$680.00+9.93%
9/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$650.00 ➝ $670.00+9.13%
9/20/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$655.00 ➝ $680.00+10.95%
9/16/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Leonard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/25/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$650.00 ➝ $660.00+9.56%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold ➝ Buy$600.00 ➝ $650.00+14.44%
4/30/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$660.00 ➝ $670.00+17.13%
4/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$600.00 ➝ $610.00+6.54%
4/10/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$550.00 ➝ $640.00+10.94%
3/18/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$620.00+6.70%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$575.00+15.58%
10/26/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Sector Weight
7/13/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$620.00+17.89%
2/2/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$620.00 ➝ $630.00+7.26%
2/2/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$690.00 ➝ $711.00+21.05%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:49 PM ET.


Should I Buy Thermo Fisher Scientific Stock? TMO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these Thermo Fisher Scientific pros and cons to contact@marketbeat.com.

Thermo Fisher Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Thermo Fisher Scientific Inc.:

  • The stock has a consensus price target of $649.33, indicating potential for growth from its current trading levels.
  • Seventeen analysts have assigned a buy rating to the stock, reflecting strong market confidence in Thermo Fisher Scientific Inc.'s future performance.
  • The company has recently seen target price increases from several analysts, suggesting positive sentiment and expectations for its financial health.
  • Thermo Fisher Scientific Inc. operates in diverse sectors including life sciences and biopharma services, which can provide stability and growth opportunities in various market conditions.
  • Insider ownership, although low at 0.34%, indicates that executives have a vested interest in the company's success, which can align their goals with those of shareholders.

Thermo Fisher Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Thermo Fisher Scientific Inc. for these reasons:

  • Recent insider selling, with a total of 47,150 shares sold valued at approximately $25.95 million, may raise concerns about the executives' confidence in the company's short-term prospects.
  • Barclays and other analysts have recently lowered their price targets, which could indicate a shift in market sentiment or concerns about future performance.
  • The stock has experienced fluctuations, with recent sales occurring at an average price of $560.16, which may suggest volatility that could deter risk-averse investors.
  • With four analysts rating the stock as a hold, there may be uncertainty about its immediate growth potential compared to other investment opportunities.
  • The competitive landscape in the life sciences sector is intense, and any significant changes in market dynamics could impact Thermo Fisher Scientific Inc.'s market position and profitability.

TMO Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Thermo Fisher Scientific is $652.30, with a high forecast of $718.00 and a low forecast of $610.00.

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Thermo Fisher Scientific in the last twelve months. There are currently 4 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TMO shares.

According to analysts, Thermo Fisher Scientific's stock has a predicted upside of 24.47% based on their 12-month stock forecasts.

Analysts like Thermo Fisher Scientific more than other "medical" companies. The consensus rating score for Thermo Fisher Scientific is 2.86 while the average consensus rating score for "medical" companies is 2.81. Learn more on how TMO compares to other companies.


This page (NYSE:TMO) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners